Peptide Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Peptide Therapeutics Market is Segmented by Marketing Type (Generic and Branded), Application (Gastrointestinal Disorders, Neurological Disorders, Metabolic Disorders, Cancer, and Other Applications), Route of Administration (Parenteral, Oral, and Other Routes of Administration), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). This Industry Report Provides the Market Value (In USD Billion) for the Above Segments.

Peptide Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Peptide Therapeutics Market Size

Peptide Therapeutics Market Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Market Size (2025) USD 46.36 Billion
Market Size (2030) USD 65.20 Billion
CAGR (2025 - 2030) 7.06 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Peptide Therapeutics Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Peptide Therapeutics Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Peptide Therapeutics Market Analysis

The Peptide Therapeutics Market size is estimated at USD 46.36 billion in 2025, and is expected to reach USD 65.20 billion by 2030, at a CAGR of 7.06% during the forecast period (2025-2030).

The major factors driving the peptide therapeutics market growth are the increasing prevalence of cancer and metabolic disorders, rising investments in research and development of novel drugs, and technological advancements in peptide therapeutics. Peptides offer distinct advantages due to their specificity and ability to target multiple biological pathways. The rising prevalence of chronic diseases significantly drives the demand for peptide therapeutic products. For example, the 2024 updated data of the American Cancer Society projects an increase in new cancer cases from 1.9 million in 2023 to 2.0 million in 2024. In 2023, the most frequently diagnosed cancers were breast, lung, and hematological malignancies. This anticipated surge in cancer cases is poised to boost the adoption of peptide therapeutics, known for their efficacy in cancer treatment.


Additionally, supportive government legislations to promote the development of therapeutic peptides is further anticipated to offer new business avenues for market uptake. For instance, in April 2023, researchers at the Georgia Institute of Technology received a USD 700,000 grant from the National Science Foundation (NSF) to strengthen the discovery of therapeutic peptides for multiple sclerosis. Such grants are likely to support the discovery of novel peptide drugs, and such instances are anticipated to fuel market growth over the study period.


Furthermore, there is a growing opportunity to combine peptide-based therapies with other treatment modalities, such as immunotherapy or biologics, to improve outcomes, especially in oncology. However, peptides are highly susceptible to enzymatic degradation and can be unstable in biological environments, which limits their therapeutic potential. Overcoming these stability issues remains a significant challenge. In addition, peptide therapeutics industry analysis shows that intellectual property concerns and the complexity of obtaining patents for peptide drugs may restrict the market potential for smaller companies and new drug developers.

Peptide Therapeutics Industry Overview

The competitive landscape of the peptide therapeutics market is dynamic, with numerous players involved in the research, development, and commercialization of peptide-based therapies. Several global pharmaceutical and biotechnology companies are leading the way, while many smaller firms and startups are driving innovation, particularly in niche areas and novel drug delivery technologies.


Some of the key players currently dominating the market are Eli Lilly and Company, Amgen Inc., Pfizer Inc., Bristol Myers Squibb Company, Ever Neuro Pharma GmbH, Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd, AstraZeneca PLC, GlaxoSmithKline PLC, Novo Nordisk AS, Novartis AG, Zealand Pharma AG, SELLAS Life Sciences Group (Galena Biopharmaceuticals). In addition, companies focus on launching new products along with approvals in various countries which is likely to increase the availability of the products in the market.


For instance, in November 2023, Eli Lilly and Company received approval from the United States Food and Drug Administration (FDA) for its Zepbound (tirzepatide) injection. Zepbound is intended for adults with obesity (BMI of 30 kg/m2 or higher) or those who are overweight (BMI of 27 kg/m2 or more) and have weight-related medical conditions such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease. In addition, advances in drug delivery systems, biosimilars, and personalized medicine are key trends that will shape the competitive dynamics in the coming years.

Peptide Therapeutics Market Leaders

  1. Eli Lilly and Company

  2. Amgen Inc.

  3. Bristol-Myers Squibb Company

  4. GlaxoSmithKline PLC

  5. AstraZeneca PLC

  6. *Disclaimer: Major Players sorted in no particular order
Peptide Therapeutics Market Competitive Landscape
Need More Details on Market Players and Competiters?
Download PDF

Peptide Therapeutics Market News

  • August 2024: Eli Lilly and Company made Zepbound (tirzepatide) available in 2.5 mg and 5 mg single-dose vials for self-pay patients holding on-label prescriptions.
  • July 2024: Pfizer Inc. revealed its preferred once-daily modified-release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist, following results from the ongoing pharmacokinetic study.
  • July 2024: AstraZeneca acquired of Amolyt Pharma, a clinical-stage biotech firm dedicated to pioneering treatments for rare endocrine disorders. This acquisition enhances the late-stage pipeline of Alexion, a part of AstraZeneca Rare Disease, and strengthens its bone metabolism portfolio.
  • June 2024: Teva Pharmaceuticals launched a generic version of Victoza, initially developed by Novo Nordisk A/S, for treating type 2 diabetes. This introduction marks the first generic GLP-1 drug in the United States, a market experiencing significant demand. Initially approved for diabetes treatment, GLP-1 drugs are also prescribed for obesity.

Peptide Therapeutics Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Cancer and Metabolic Disorders
    • 4.2.2 Rising Investments in Research and Development of Novel Drugs
    • 4.2.3 Technological Advancements
  • 4.3 Market Restraints
    • 4.3.1 Instability of Peptides
    • 4.3.2 High Cost of Developing Drugs and Stringent Regulatory Requirements for Drug Approval
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value in USD billion)

  • 5.1 By Marketing Type
    • 5.1.1 Generic
    • 5.1.2 Branded
  • 5.2 By Application
    • 5.2.1 Gastrointestinal Disorders
    • 5.2.2 Neurological Disorders
    • 5.2.3 Metabolic Disorders
    • 5.2.4 Cancer
    • 5.2.5 Other Applications
  • 5.3 By Route of Administration
    • 5.3.1 Parenteral
    • 5.3.2 Oral
    • 5.3.3 Other Routes of Administration
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Eli Lilly and Company
    • 6.1.2 Amgen Inc.
    • 6.1.3 Pfizer Inc.
    • 6.1.4 Bristol-Myers Squibb Company
    • 6.1.5 Ever Neuro Pharma GmbH
    • 6.1.6 Takeda Pharmaceutical Company Limited
    • 6.1.7 Teva Pharmaceuticals Industries Ltd
    • 6.1.8 AstraZeneca PLC
    • 6.1.9 GlaxoSmithKline PLC
    • 6.1.10 Novo Nordisk AS
    • 6.1.11 Novartis AG
    • 6.1.12 Zealand Pharma AG
    • 6.1.13 SELLAS Life Sciences Group (Galena Biopharmaceuticals)
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Peptide Therapeutics Industry Segmentation

As per the report's scope, Peptides are short chains of amino acid monomers linked by peptide bonds. Peptides are distinguished from proteins based on size and, as a benchmark, can be understood to contain approximately 50 amino acids or less.


The peptide therapeutics market segmentation includes marketing type, application, route of administration, and geography. By marketing type, the market is segmented into generic, and branded. By application, the market is segmented into gastrointestinal disorders, neurological disorders, metabolic disorders, cancer, and other applications. By route of administration, the market is segmented into parenteral, oral, and other routes of administration. By geography, the global market is segmented into North America (United States, Canada, Mexico), Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, Rest of Middle East and Africa), and South America (Brazil, Argentina, Rest of South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the market value (in USD billion) for the above segments. By Marketing Type Generic   Branded By Application Gastrointestinal Disorders   Neurological Disorders Metabolic Disorders Cancer Other Applications By Route of Administration Parenteral   Oral   Other Route of Administration   By Geography North America United States Canada Mexico Europe Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific China Japan India Australia South Korea Rest of Asia Pacific Middle East and Africa GCC South Africa Rest of Middle East and Africa South America Brazil Argentina Rest of South America

By Marketing Type Generic
Branded
By Application Gastrointestinal Disorders
Neurological Disorders
Metabolic Disorders
Cancer
Other Applications
By Route of Administration Parenteral
Oral
Other Routes of Administration
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Peptide Therapeutics Market Research FAQs

How big is the peptide industry?

The peptide therapeutics market size is expected to reach USD 43.36 billion in 2025 and grow at a CAGR of 7.06% to reach USD 65.20 billion by 2030.

What are the challenges of peptide therapeutics?

The key challenges hindering the growth of the peptide therapeutics market are high production costs, complex manufacturing processes, and limited commercialization of peptide drugs.

What is the future of peptide therapeutics?

The future of peptide therapeutics looks promising, with advancements in drug design, targeted delivery systems, and personalized medicine poised to enhance their efficacy and expand their applications in treating a wide range of diseases.

What is the market outlook for peptides?

The market for peptides is expected to experience significant growth, driven by increasing demand for peptide-based drugs, advancements in peptide synthesis technologies, and expanding applications in oncology, metabolic disorders, and autoimmune diseases.

What are the disadvantages of peptide therapeutics?

Peptide therapeutics face challenges such as poor oral bioavailability, susceptibility to enzymatic degradation, and high production costs.

Peptide Therapeutics Market Report Snapshots